Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Saturday, May 23, 2026




In Detail Full day, Saturday, May 23, 2026, Timezone: America/Chicago


Stem cells have potent potential for diabetes treatment

medicalxpress - Humans have around 30 trillion cells in our adult bodies. Amazingly, each of these cells came from a handful of about 100 stem cells in the earliest days of development. The ability of these embryonic stem cells to turn into any cell type makes them pluri…

AI Summary: Researchers report stem cell–based approaches can replenish insulin‑producing cells and restore glycemic control in diabetes models, offering a potential path beyond daily insulin injections. Early findings suggest significant therapeutic promise, but scientists stress that safety, durability, and immune‑rejection hurdles must be cleared before these techniques graduate from experimental hope to standard care.

#healthcare #pharmaceuticals #biotech #drugdevelopment #clinicaltrials #diabetes #genetherapy

5 days / medicalxpress

7 days / livescience

8 days / medicalxpress


Back to Top / Saturday, May 23, 2026, 4:21 pm / permalink 24259 / 4 stories in 8 days /

An Ebola treatment tent is set ablaze again in eastern Congo with 18 suspected cases escaping

abcnews - A tent used for Ebola treatment in eastern Congo has been set on fire for the second time this week

AI Summary: In eastern Congo, an Ebola treatment tent was set ablaze, allowing at least 18 suspected patients to escape and disrupting outbreak containment efforts. The incident has drawn international scrutiny, with Congolese health officials publicly criticizing restrictive U.S. travel measures that complicate cross-border response and community trust.

#healthcare #publichealth #governmentpolicy #hospitaloperations #zoonoticdisease #infectiousdisease #healthdisparities

Response failures and international policy criticism

6 days / medicalxpress


Rising caseloads and cross-border spread concerns

6 days / medicalxpress

7 days / abcnews

7 days / medicalxpress


Violent attacks and community resistance at treatment sites

6 days / medicalxpress

7 days / abcnews

7 days / abcnews

8 days / abcnews


All Other Stories

38 hrs / abcnews

41 hrs / kffhealthnews

2 days / medicalxpress

2 days / medicalxpress

2 days / abcnews

2 days / abcnews

2 days / abcnews

3 days / medicalxpress

4 days / medicalxpress

4 days / medicalxpress

4 days / abcnews

4 days / abcnews

4 days / abcnews

5 days / medicalxpress

5 days / medicalxpress

6 days / medicalxpress

6 days / abcnews

6 days / medicalxpress

6 days / medicalxpress

8 days / kffhealthnews


Back to Top / Saturday, May 23, 2026, 12:21 pm / permalink 24248 / 35 stories in 8 days /

Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Ayisha Sharma / endpoints - Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s ...

AI Summary: After disappointing mid‑stage results, developers have stopped advancement of a candidate Parkinson’s therapy for non‑genetic forms of the disease. The setback underscores the challenges of translating promising mechanisms into clinical benefit and will force sponsors to reassess pipelines and patient selection strategies.

#healthcare #pharmaceuticals #biotech #drugdevelopment #researchfunding #clinicaltrials #neuroscience

4 days / nature

5 days / medicalxpress


Back to Top / Saturday, May 23, 2026, 9:20 am / permalink 24241 / 5 stories in 8 days /

Abridge names chief technology officer

Giles Bruce / beckershospitalreview - San Oo has been named chief technology officer of healthcare AI startup Abridge. Mr. Oo was most recently senior vice president of engineering at AI workspace developer Notion. He previously cofounded two tech companies that were acquired by LinkedIn and …

AI Summary: Abridge has appointed a new chief technology officer to lead its product and engineering strategy, signaling a push to scale its clinical AI tools and platform capabilities. The hire aims to strengthen technical leadership, accelerate development timelines, and reassure customers that the company intends to keep up with the fast-paced demands of healthcare AI — which, ironically, keeps hiring to stop churn.

#healthcare #digitalhealth #healthit

AI startups scale via health system partnerships


Practical challenges: accessibility, training, oversight of clinical AI

6 days / oncodaily

7 days / oncodaily


All Other Stories

11 hrs / medicalxpress

4 days / medicalxpress

7 days / oncodaily


Back to Top / Saturday, May 23, 2026, 6:21 am / permalink 24239 / 18 stories in 8 days /

CommonSpirit $3.4B in the red amid billing contract exit, operational woes

Rebecca Pifer Parduhn / healthcaredive - The Catholic nonprofit giant’s expenses well outstripped revenue in the most recent financial quarter. Though the outcome was mostly due to one-time items, CommonSpirit also continues to struggle with boosting core operations.

AI Summary: CommonSpirit reported a multi‑billion‑dollar shortfall tied to operational challenges and the exit from a major billing contract, recording a substantial loss and a weakened operating margin in the quarter. The results have spurred leadership to reassess financial strategy and cost controls as the system navigates recovery and operational stabilization.

#healthcare #hospitaloperations #healthcarefinance #healthit

Back to Top / Saturday, May 23, 2026, 2:21 am / permalink 24235 / 6 stories in 8 days /

Nearly 10% of surgeons are leaving the profession within 8 years

medicalxpress - Surgeons are an integral part of the health care system, supplying critical and urgent care in nearly every field of medicine. But surgeons are already in short supply, with the gap between the number needed and the number working expected to get worse.

AI Summary: A recent report reveals that roughly one in ten surgeons leave clinical practice within eight years of starting, spotlighting a troubling attrition rate that threatens surgical capacity. The findings point to burnout, workload and systemic pressures as likely drivers and underscore the need for retention strategies, training support and policy changes to stabilize the surgical workforce.

#healthcare #publichealth #governmentpolicy #behavioralhealth #hospitaloperations #healthcarefinance #healthdisparities

11 days / medicalxpress


Back to Top / Saturday, May 23, 2026, 1:21 am / permalink 24231 / 6 stories in 8 days /

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...

AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #oncology #healthcarefinance #cancerresearch #clinicaltrials

Clinicians weigh Datroway’s role in TNBC care

7 days / oncodaily

7 days / oncodaily

8 days / oncodaily


FDA win and market stakes for Datroway

7 days / oncodaily


All Other Stories

2 days / oncodaily

3 days / oncodaily

3 days / oncodaily

6 days / medicalxpress

6 days / oncodaily

7 days / oncodaily

7 days / oncodaily

7 days / oncodaily

8 days / oncodaily

9 days / bbc


Back to Top / Saturday, May 23, 2026, 1:21 am / permalink 24230 / 16 stories in 8 days /

Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer

Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…

AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.

#healthcare #oncology #pancreaticcancer #cancerresearch #cancerscreening #diagnostics

2 days / oncodaily

2 days / newscientist

4 days / oncodaily

10 days / medicalxpress


Back to Top / Saturday, May 23, 2026, 12:22 am / permalink 24227 / 5 stories in 8 days /



StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Gene Therapy, Cancer Research, Infectious Disease and look for the RSS link.

More StackHealth





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.